Peer-reviewedCC BYEClinicalMedicine
Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
Related
- Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
- Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
- Effectiveness and safety of cefazolin vs antistaphylococcal penicillins for methicillin-susceptible Staphylococcus aureus bacteremia: a multicenter real-world evaluation using the international TriNetX database
- Analysis of key performance indicators influencing offensive effectiveness during clutch moments in elite international men’s basketball
- Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
BibTeX
@article{law2026costeffectiveness,
title = {{Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)}},
author = {Chi Kin Law and Martin R. Stockler and Andrew J. Martin and Ian D. Davis and Christopher J. Sweeney and Rachael L. Morton},
journal = {EClinicalMedicine},
year = {2026},
month = oct,
doi = {10.1016/j.eclinm.2026.104207},
url = {https://europepmc.org/article/PMC/PMC13673054},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
AU - Chi Kin Law
AU - Martin R. Stockler
AU - Andrew J. Martin
AU - Ian D. Davis
AU - Christopher J. Sweeney
AU - Rachael L. Morton
PY - 2026
DA - 2026/10/01
JO - EClinicalMedicine
DO - 10.1016/j.eclinm.2026.104207
UR - https://europepmc.org/article/PMC/PMC13673054
SN - 2589-5370
ER -